Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To estimate the proportion of objective responders over 52 weeks to ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia (CLL)who progressed following response or stable disease after ofatumumab treatment in an ongoingclinical trial, Hx-CD20-406.
Critère d'inclusion
- B-cell Chronic Lymphocytic Leukemia (CLL)